Your browser doesn't support javascript.
loading
An inflammatory liquid fingerprint predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.
Yang, Modan; Lin, Zuyuan; Zhuang, Li; Pan, Linhui; Wang, Rui; Chen, Hao; Hu, Zhihang; Shen, Wei; Zhuo, Jianyong; Yang, Xinyu; Li, Huigang; He, Chiyu; Yang, Zhe; Xie, Qinfen; Dong, Siyi; Chen, Junli; Su, Renyi; Wei, Xuyong; Yin, Junjie; Zheng, Shusen; Lu, Di; Xu, Xiao.
Affiliation
  • Yang M; Department of Breast Surgery The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou China.
  • Lin Z; NHC Key Laboratory of Combined Multi-Organ Transplantation Zhejiang University Hangzhou China.
  • Zhuang L; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University Hangzhou China.
  • Pan L; Zhejiang University School of Medicine Hangzhou China.
  • Wang R; Department of Hepatobiliary and Pancreatic Surgery Shulan (Hangzhou) Hospital Hangzhou China.
  • Chen H; Department of Hepatobiliary and Pancreatic Surgery Affiliated Hangzhou First People's Hospital School of Medicine Westlake University Hangzhou China.
  • Hu Z; Zhejiang University School of Medicine Hangzhou China.
  • Shen W; Zhejiang University School of Medicine Hangzhou China.
  • Zhuo J; Zhejiang University School of Medicine Hangzhou China.
  • Yang X; Zhejiang University School of Medicine Hangzhou China.
  • Li H; Department of Hepatobiliary and Pancreatic Surgery Affiliated Hangzhou First People's Hospital School of Medicine Westlake University Hangzhou China.
  • He C; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University Hangzhou China.
  • Yang Z; Zhejiang University School of Medicine Hangzhou China.
  • Xie Q; Zhejiang University School of Medicine Hangzhou China.
  • Dong S; Zhejiang University School of Medicine Hangzhou China.
  • Chen J; Department of Hepatobiliary and Pancreatic Surgery Shulan (Hangzhou) Hospital Hangzhou China.
  • Su R; Department of Hepatobiliary and Pancreatic Surgery Shulan (Hangzhou) Hospital Hangzhou China.
  • Wei X; National Center for Healthcare Quality Management in Liver Transplant Hangzhou China.
  • Yin J; National Center for Healthcare Quality Management in Liver Transplant Hangzhou China.
  • Zheng S; Zhejiang University School of Medicine Hangzhou China.
  • Lu D; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University Hangzhou China.
  • Xu X; Department of Hepatobiliary and Pancreatic Surgery Affiliated Hangzhou First People's Hospital School of Medicine Westlake University Hangzhou China.
MedComm (2020) ; 5(9): e678, 2024 Sep.
Article de En | MEDLINE | ID: mdl-39188937
ABSTRACT
Tumor recurrence is a life-threatening complication after liver transplantation (LT) for hepatocellular carcinoma (HCC). Precise recurrence risk stratification before transplantation is essential for the management of recipients. Here, we aimed to establish an inflammation-related prediction model for posttransplant HCC recurrence based on pretransplant peripheral cytokine profiling. Two hundred and ninety-three patients who underwent LT in two independent medical centers were enrolled, and their pretransplant plasma samples were sent for cytokine profiling. We identified four independent risk factors, including alpha-fetoprotein, systemic immune-inflammation index, interleukin 6, and osteocalcin in the training cohort (n = 190) by COX regression analysis. A prediction model named inflammatory fingerprint (IFP) was established based on the above factors. The IFP effectively predicted posttransplant recurrence (area under the receiver operating characteristic curve [AUROC] 0.792, C-index 0.736). The high IFP group recipients had significantly worse 3-year recurrence-free survival rates (37.9 vs. 86.9%, p < 0.001). Simultaneous T-cell profiling revealed that recipients with high IFP were characterized by impaired T cell function. The IFP also performed well in the validation cohort (n = 103, AUROC 0.807, C-index 0.681). In conclusion, the IFP efficiently predicted posttransplant HCC recurrence and helped to refine pretransplant risk stratification. Impaired T cell function might be the intrinsic mechanism for the high recurrence risk of recipients in the high IFP group.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: MedComm (2020) Année: 2024 Type de document: Article Pays de publication: Chine

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: MedComm (2020) Année: 2024 Type de document: Article Pays de publication: Chine